Comparison of the Effect of Medication Therapy in Alleviating Migraine With Patent Foramen Ovale
Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
Migraine attack is an episodic disorder that affects approximately 12% of the population.
Previous studies have shown that 41-48% of migraineur have a combination of patent foramen
ovale (PFO). Clinical observational studies have been linking medication therapies which
include anticoagulation and anti-platelet therapy with the effectiveness in improving
migraine symptoms and reducing the frequency of attacks in patients combined with a PFO.
However, it has been unclear whether the effectiveness of anticoagulation or anti-platelet
therapy outweigh the conventional migraine medication therapy, as a result, we designed a
multi-center randomized clinical trial aiming to examine the effectiveness of anticoagulation
versus anti-platelet versus migraine medication therapy in migraine patients with PFO and
provide a clinical guidance for migraineur.
Phase:
Phase 4
Details
Lead Sponsor:
Chinese Academy of Medical Sciences, Fuwai Hospital